A new conjugate vaccine for cholera has been developed. The invention includes a new method to conjugate the O-specific polysaccharide-core part of the bacterial lipopolysaccharide and protein subcomponents. Conventional technology has entailed chemical treatment of both components to introduce linkers, which made them amenable for covalent linking. The new method simplifies production by utilizing squaric acid chemistry for conjugating the free amine-containing species (e.g. polysaccharides) directly to amine-containing species (e.g. proteins) without prior modification of either component. While demonstrated in this new cholera prototype vaccine, the technology is envisioned as generally applicable, thereby streamlining a complex production process.
CRADA Opportunity: The National Institute of Diabetes and Digestive and Kidney Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize conjugate vaccines. For collaboration opportunities, please contact Marguerite J. Miller, M.B.A. at 301-496-9003 or
millermarg@niddk.nih.gov.
Source: http://www.ott.nih.gov/Technologies/abstractDetails.aspx?RefNo=2349
Jennifer Morrison Jennifer ODell Jennifer Scholle Jennifer Sky Jenny McCarthy
No comments:
Post a Comment